References
- 1. Jurisson, S., & Lydon, S. (1999). Potential technetium small molecule radiopharmaceuticals. Chem. Rev., 99(9), 2205–2218. DOI: 10.1021/cr980435t.
- 2. Fleisch, H. A. (1998). Bisphosphonates: mechanisms of action. Endocr. Rev., 19(1), 80–100.
- 3. Papapoulos, S. E. (1995). Pharmacodynamics of bisphosphonates in man. In O. Bijvoet, H. Fleisch, R. E. Comfield, & G. G. Russell (Eds.), Bisphosphates on bone (Chapter 15). Amsterdam: Elsevier Science B.V.
- 4. Subramanian, G., McAfee, J. G., Blair, R. J., Kallfelz, F. A., & Thomas, F. D. J. (1975). Technetium-99m-methylene diphosphonate – a superior agent for skeletal imaging: comparison with other technetium complexes. J. Nucl. Med., 16(8), 744–755. DOI: 10.2174/092986712801215865.
- 5. Bevan, J. A., Tofe, A. J., Benedict, J. J., Francis, M. D., & Barnett, B. L. (1980). Tc-99m HMDP (HydroxymethyleneDiphosphonate): A radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals. J. Nucl. Med., 21(10), 961–966. DOI: 10.2174/092986712801215865.
- 6. Bartholoma, M. D., Louie, A. S., Valliant, J. F., & Zubieta, J. (2010). Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. J. Chem. Rev., 110(5), 2903–2920. DOI: 10.1021/cr1000755.
- 7. Russell, R. G. G., & Fleisch, H. (1975). Pyrophosphate and diphosphonates in skeletal metabolism. Clin. Orthop., 108, 241–263.
- 8. Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983). Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int., 35, 87–99. DOI: 10.1007/BF02405012.
- 9. Schenk, R., Eggli, P., Fleisch, H., & Rosini, S. (1986). Quantitative morphometric evaluation of the inhibitory activity of new. Amino bisphosphonates on bone resorption in the rat. Calcif. Tissue Int., 38, 342–349. DOI: 10.1007/BF02555748.
- 10. Pluijm, G. V. D., Binderup, L., Bramm, E., Wee-Pals, L. V. D., Groot, H. D., & Binderup, E. (1992). Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. J. Bone Miner. Res., 7, 981–986. DOI: 10.1002/jbmr.5650070815.
- 11. Sato, M., & Grasser, W. (1990). Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res., 5, 31–40. DOI: 10.1002/jbmr.5650050107.
- 12. Rudd, T. G., Allen, D. R., & Hartnett, D. E. (1977). Tc-99m methylene diphosphonate versus Tc-99m pyrophosphate: biologic and clinical comparison. J. Nucl. Med., 18, 872–876.
- 13. Lin, W. Y., & Wang, S. J. (1996). The influence of two bone agents (Tc-99m pyrophosphate and Tc-99m methylenediphosphonate) on quantitative sacroiliac joint scintigraphy. Nucl. Med. Commun., 17, 1035–1038.
- 14. Imanishi, Y., Mitogawa, Y., Takizawa, M., Konno, S., Samura, H., & Ohsawa, A. (1999). Relapsing polychondritis diagnosed by Tc-99m MDP bone scintigraphy. Clin. Nucl. Med., 24, 511–513.
- 15. Altomare, A., Cuocci, C., Giacovazzo, C., Moliterni, A., & Rizzi, R. (2008). A computer program for qualitative analysis using powder diffraction data. J. Appl. Cryst., 41, 815–817. DOI: 10.1107/S0021889808016956.
- 16. Tsaryk, N. V., Dudko, A. V., Kozachkova, A. N., & Pekhnyo, V. I. (2011). A second triclinic polymorph of (1-ammonio-1-phosphonoethyl) phosphonate. Acta Crystallogr. Sect. E-Struc. Rep. Online, 67, o1651–o1652. DOI: 10.1107/S1600536811022239.